2011
Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21‐Gene Recurrence Score
Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Goetz MP. Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21‐Gene Recurrence Score. The Oncologist 2011, 16: 1359-1366. PMID: 21934103, PMCID: PMC3228065, DOI: 10.1634/theoncologist.2011-0048.Peer-Reviewed Original ResearchConceptsRecurrence scorePrognostic criteriaRS riskTreatment recommendationsIntermediate-risk casesHormone receptor statusLymph node negativeProspective clinical trialsStandard prognostic factorsIntermediate recurrence scoreAbility of oncologistsChemotherapy useChemotherapy recommendationsChemotherapy benefitNode negativePrognostic factorsReceptor statusHistologic typeAcademic oncologistsOncologists' useTumor gradeClinical trialsBreast cancerRS categoryOncologist's ability
2007
Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI
Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI. European Journal Of Cancer 2007, 43: 1646-1653. PMID: 17512721, DOI: 10.1016/j.ejca.2007.04.006.Peer-Reviewed Original ResearchConceptsCycles of CMFInternational Breast Cancer Study Group Trial VBreast cancerPremature menopauseCox proportional hazards modelTrial VEarly breast cancerLong-term resultsAge of menopauseProportional hazards modelAdjuvant chemotherapyMenses dataTemporary amenorrheaBilateral oophorectomyPremenopausal womenNode negativeSystemic therapyChemotherapyHazards modelMenopauseTrial VIEarly onsetWomenCancerTemporary cessation